# Resource Summary Report

Generated by RRID on Sep 9, 2026

## MDA231-LM2-4142

RRID:CVCL_DG21
Type: Cell Line

### Proper Citation

RRID:CVCL_DG21

### Cell Line Information

**URL:** https://web.expasy.org/cellosaurus/CVCL_DG21

**Proper Citation:** RRID:CVCL_DG21

**Description:** Cell line MDA231-LM2-4142 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Breast adenocarcinoma

**Defining Citation:** PMID:16049480

**Comments:** Characteristics: Established from MDA231-TGL cell line after 3 passage in nude mice., Population: Caucasian., Group: Triple negative breast cancer (TNBC) cell line.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** MDA231-LM2-4142

**Synonyms:** MDA 231-LM2-4142, MDA-MB-231 #4142, LM2-4142, 4142

**Cross References:** cancercelllines:CVCL_DG21, GEO:GSM50017, GEO:GSM587389, Wikidata:Q54904665

**ID:** CVCL_DG21

**Hierarchy:** cvcl_vr35

**Record Creation Time:** 20220427T220756+0000

**Record Last Update:** 20260905T181123+0000

## Ratings and Alerts

No rating or validation information has been found for MDA231-LM2-4142.

No alerts have been found for MDA231-LM2-4142.

## Data and Source Information

**Source:** Cellosaurus

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at RRID .

Adeleye KL, et al. (2026) A novel colchicine-binding site inhibitor suppresses triple-negative breast cancer growth and metastasis and synergizes with anti-PD-L1 immunotherapy in an immunogenic cancer model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 198, 119353.